Brokerages predict that AVROBIO, Inc. (NASDAQ:AVRO – Get Rating) will announce earnings per share of ($0.54) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for AVROBIO’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.62). AVROBIO posted earnings per share of ($0.74) during the same quarter last year, which suggests a positive year over year growth rate of 27%. The business is scheduled to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that AVROBIO will report full-year earnings of ($2.15) per share for the current fiscal year, with EPS estimates ranging from ($2.46) to ($1.41). For the next year, analysts forecast that the business will report earnings of ($1.82) per share, with EPS estimates ranging from ($2.19) to ($1.05). Zacks’ EPS averages are a mean average based on a survey of research analysts that follow AVROBIO.
AVROBIO (NASDAQ:AVRO – Get Rating) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.10).
AVRO stock traded up $0.03 during mid-day trading on Friday, reaching $0.81. 352,023 shares of the stock traded hands, compared to its average volume of 476,634. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.27 and a current ratio of 9.98. AVROBIO has a one year low of $0.75 and a one year high of $11.00. The stock has a market capitalization of $35.23 million, a PE ratio of -0.29 and a beta of 1.73. The business has a 50-day moving average price of $1.20 and a two-hundred day moving average price of $2.49.
Institutional investors have recently modified their holdings of the business. Point72 Hong Kong Ltd bought a new position in AVROBIO during the 3rd quarter worth about $26,000. Penn Mutual Asset Management LLC bought a new position in AVROBIO during the 1st quarter worth about $49,000. BNP Paribas Arbitrage SA lifted its position in shares of AVROBIO by 112.5% during the third quarter. BNP Paribas Arbitrage SA now owns 9,665 shares of the company’s stock valued at $54,000 after buying an additional 5,117 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of AVROBIO during the third quarter valued at about $63,000. Finally, Marshall Wace LLP purchased a new stake in shares of AVROBIO during the third quarter valued at about $63,000. Institutional investors own 63.92% of the company’s stock.
About AVROBIO (Get Rating)
AVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease.
- Get a free copy of the StockNews.com research report on AVROBIO (AVRO)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.